{"id":7770,"date":"2018-10-15T18:01:26","date_gmt":"2018-10-15T22:01:26","guid":{"rendered":"http:\/\/localhost:10028\/uncategorized\/what-you-should-know-about-fourniers-gangrene\/"},"modified":"2022-08-18T21:16:13","modified_gmt":"2022-08-19T01:16:13","slug":"what-you-should-know-about-fourniers-gangrene","status":"publish","type":"post","link":"https:\/\/napolilaw.lemonadestand.org\/en\/article\/what-you-should-know-about-fourniers-gangrene\/","title":{"rendered":"What You Should Know About Fournier\u2019s Gangrene"},"content":{"rendered":"

The U.S. Food and Drug Administration (FDA)<\/a> issued a warning in late August 2018 about the link between diabetic medications and a rare, yet life-threatening disease called Fournier\u2019s gangrene. The warning is specific to certain FDA-approved inhibitors (SGLT2), which are said to prevent the kidneys<\/a> from reabsorbing sugar into the blood, therefore helping lower blood sugar, and the risk for heart attack and stroke in adults with type 2 diabetes<\/a>. These medications include, but are not limited to, Invokana, Jardiance, and other SGLT2 inhibitors produced and distributed by global pharmaceutical companies. The warning was issued as a result of 12 confirmed cases of Fournier\u2019s gangrene linked to taking SGLT2 inhibitors between March 2013 and May 2018. The FDA\u2019s warning states that while there are only 12 confirmed cases linked to SGLT2 inhibitors, to include seven men and five women, the estimated 1.7 million patients who were prescribed these inhibitors in 2017 may potentially be at risk. The pharmaceutical attorneys at Napoli Shkolnik , along with the FDA, urge any individuals who are or may be experiencing symptoms to seek medical attention immediately. For patients and health professionals who notice side effects from using SGLT2 inhibitors, the FDA requests that you report your symptoms to the FDA MedWatch<\/a> reporting program right away.<\/p>\n

Today, the pharmaceutical lawyers at Napoli Shkolnik will share useful statistics and facts, and explain the risk factors and symptoms of Fournier\u2019s gangrene. Should you or a loved one fall under the common risk factors or display symptoms, contact a health professional immediately. Then, reach out to Napoli Shkolnik \u2019s dedicated pharmaceutical litigation<\/a> team to discuss your potential claim.<\/p>\n

Understanding Fournier\u2019s Gangrene<\/h2>\n

The Mayo Clinic<\/a> defines gangrene as the \u201cdeath of body tissue due to lack of blood flow or serious bacterial infection,\u201d which typically affects the extremities. Fournier’s gangrene is a necrotizing infection<\/a> that is extremely rare, yet often disfiguring and even fatal. This serious bacterial infection affects the tissue under the skin surrounding the soft tissues (muscles, nerves, blood vessels, and fat) of the genital organs; more specifically, the perineum between the vulva and scrotum. While Fournier\u2019s gangrene typically affects men, there have been known cases in women and children.<\/p>\n

Useful Stats and Facts<\/h3>\n